Ryan Bond
About Ryan Bond
Ryan Bond is Chief Strategy Officer of Aclarion (ACON) and has served in this role since September 2021. He previously served as Vice President, Business Development (Dec 2018–Aug 2021), where he led business development, sales and marketing, coordinated customer-sponsored research trials, and advanced reimbursement by securing Category III CPT codes and advocating for CMS policy changes on MRS (CPT 76390) . He holds a B.S. in Engineering from Ohio University’s Russ College of Engineering and Technology, and serves on an advisory board to the College of Business at Ohio University . Public filings reviewed do not disclose his age or company TSR/revenue/EBITDA growth attribution for his tenure; the company describes its program as “pay for performance” with base salary, discretionary bonus, and equity incentives .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Aclarion, Inc. | Vice President, Business Development | Dec 2018–Aug 2021 | Led BD, sales and marketing; limited commercial SaaS launch in US/EU/UK; coordinated customer-sponsored research trials; advanced reimbursement (Category III CPT codes; advocated to CMS) |
| NuVasive | Director, Healthcare Solutions | Nov 2014–Sep 2018 | Led strategic partnerships, channel development, pricing/contracting, sales training in global spine market |
| Accelero Health Partners (acquired by Zimmer in 2006) | Executive/Consultant | 2005–2014 | Built musculoskeletal service line programs using BI tools; firm acquired by Zimmer (2006) |
External Roles
| Organization | Role | Years | Notes |
|---|---|---|---|
| Ohio University, College of Business | Advisory Board Member | — | Advisory board service; B.S. Engineering from Russ College of Engineering and Technology |
Fixed Compensation
| Metric | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Base Salary ($) | 185,417 | 200,000 | 200,000 | 200,000 |
Performance Compensation
Annual Cash Bonus (Discretionary)
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Plan Type / Metrics | Cash bonus from temporary salary deferral program (no formulaic metrics disclosed) | Discretionary annual cash bonus (committee approval Mar 2023; payment contingent on liquidity at the time) | Discretionary annual cash bonus; approved Jun 2024 | Discretionary annual cash bonus; approved Jan 2025 |
| Payout ($) | 17,188 | 19,532 | 11,125 | 26,875 |
The company describes its executive bonus program as discretionary and does not disclose metric weightings/targets for Mr. Bond (e.g., revenue/EBITDA/TSR) in the DEF 14A materials reviewed .
Equity Awards (Options)
-
Outstanding as of December 31, 2022 (pre-reverse split): | Grant Date | Instrument | Exercisable (#) | Unexercisable (#) | Exercise Price ($) | Expiration | |---|---|---:|---:|---:|---| | 02/19/2019 | Stock Option | 21,419 | — | 1.34 | 02/19/2029 | | 09/04/2021 | Stock Option | 6,108 | — | 1.94 | 09/04/2031 |
-
Outstanding as of December 31, 2023 (post-Jan 3, 2024 reverse split adjustment): | Grant Date | Instrument | Exercisable (#) | Unexercisable (#) | Exercise Price ($) | Expiration | |---|---|---:|---:|---:|---| | 02/19/2019 | Stock Option | 1,339 | — | 21.44 | 02/19/2029 | | 09/04/2021 | Stock Option | 382 | — | 31.04 | 09/04/2031 |
Equity grant date fair-values were not reported for Mr. Bond in 2023–2024; his 2021 total included $3,983 in option award value (ASC 718) .
Equity Ownership & Alignment
| Metric | Sep 30, 2023 | Aug 20, 2024 | Nov 30, 2024 | Feb 3, 2025 |
|---|---|---|---|---|
| Common Shares | 20,000 | 1,250 | 1,250 | 1,250 |
| Vested Options | 27,527 | 1,721 | 1,721 | 1,721 |
| IPO Warrants | 21,000 | 1,313 | 1,313 | 1,313 |
| Total Beneficial Ownership (shares/derivatives) | 68,527 (0.8%) | 4,284 (<1%) | 4,284 (<1%) | 4,284 (<1%) |
- Company insider trading policy: prohibits derivative transactions in company stock by executives/directors (except publicly traded common stock warrants); highlights risks of securities held in margin accounts or pledged as collateral; Rule 10b5-1 plans permitted .
- No pledging by Mr. Bond is disclosed in beneficial ownership footnotes reviewed .
Employment Terms
- Role and start: Chief Strategy Officer since September 2021 .
- Clawback policy: Effective December 1, 2023; no recoveries required for the prior three years as of adoption; policy filed as Exhibit 97 to 2023 Form 10-K .
- Trading policies: Rule 10b5-1 plans allowed; derivatives prohibited (except company warrants); policy notes risks of margin/pledging but does not state an explicit ban in the excerpts reviewed .
- Severance/Change-in-control: Not disclosed for Mr. Bond in the DEF 14A excerpts reviewed (agreements disclosed in detail for CEO/CFO only) .
Governance Context (Compensation Committee)
- 2024 composition: Amanda Williams, Scott Breidbart, and Bill Wesemann (chair); all independent under Nasdaq rules; committee met 2 times in FY 2024 .
- 2023 composition: Same members; 6 meetings in FY 2023 .
Performance & Track Record
- Strategic achievements cited: Led limited commercial launch of SaaS product with early adopters in US/EU/UK; coordinated customer-sponsored research trials; secured Category III CPT codes; advocated for CMS policy change on MRS reimbursement .
- No legal proceedings adverse to the company involving executive officers disclosed in the proxies reviewed .
Compensation Structure Analysis
- Cash vs equity mix: 2023–2024 compensation for Mr. Bond comprised base salary and discretionary cash bonus; no new equity awards disclosed in those years for him in the proxies reviewed .
- Discretionary bonuses: Company uses a discretionary annual cash bonus program; 2022 bonuses (companywide) were approved but payment timing was contingent on liquidity at that time, indicating cash constraints that could influence realized pay and retention .
- Option profile: Outstanding options are legacy grants (2019, 2021) with post-split exercise prices of $21.44 and $31.04 and expirations in 2029/2031, respectively, which may reduce near-term in-the-money value and selling pressure unless shares appreciate materially .
Investment Implications
- Alignment: Mr. Bond’s beneficial ownership is small (<1%) post-split (4,284 combined shares/options/warrants as of late 2024/early 2025), limiting direct equity alignment vs peers but consistent with the company’s overall low insider percentages following capital structure changes .
- Selling pressure: No Form 4 data reviewed here; option inventory is limited and out-of-the-money post-split (exercise prices $21.44/$31.04), which reduces near-term exercise/sale incentives; 10b5-1 sales are permitted, and derivatives other than public warrants are restricted by policy .
- Pay-for-performance: Bonuses are discretionary without disclosed financial metrics/weightings; 2023 and 2024 payouts were modest ($11,125; $26,875) vs $200k salary, suggesting limited variable pay magnitude; lack of formulaic metrics may weaken line-of-sight incentives for value creation .
- Retention/cash constraints: Prior disclosure that 2022 bonuses were approved but held for liquidity underscores historical cash tightness, a potential retention risk if cash bonuses are delayed again in future periods .
- Governance safeguards: Clawback policy (effective Dec 1, 2023) and insider trading controls (derivative prohibition; 10b5-1 permitted) are in place; compensation committee independence and activity provide oversight .
References: